Due to the fact that these mice developed such apparent Aβ pathology and memory deficits as early as 6 months of age, the APP/PS1 model is valuable in studying the development of new therapeutic approaches targeted against amyloid as well as AD-related microglial dysfunction and vesicle trafficking impairment. Here, PSEN1 is linked to Alzheimer disease.